Matthen Mathew is an Oncology physician affiliated with Boca Raton Regional Hospital. OpenAlex indexes 23 publications with 547 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
701 NW 13th St Fl 2
Boca Raton, FL 334862305
Telephone
561-955-6400Provider last certified this registry record 21 Sept 2021.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Galvanize Therapeutics, IncProgram year20251 payment
- Daiichi Sankyo Inc.Program year20253 payments
- E.R. Squibb & Sons, L.L.C.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
43.8%Kinase inhibitor32%Tagrisso84%Gilotrif16%Part D<11 patientsOther antineoplastic agents11.8%Lumakras100%Part D<11 patientsMetabolism & gastrointestinal
24.3%Corticosteroid20.2%Prednisone100%Part D≥29 patientsAntidiarrheal4%Diphenoxylate-Atropine100%Part D<11 patientsBlood & clotting
11.8%Factor Xa inhibitor11.8%Eliquis100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 516 An open-label, phase II multicenter study of rituximab or tocilizumab for steroid-dependent or steroid-refractory immune-related adverse events due to immune checkpoint inhibitors
Regular and Young Investigator Award Abstracts
2025 - INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors
Cancer Immunology Immunotherapy
2024 - 760 Interim PK/PD, safety and efficacy data of monotherapy dose escalation of a phase 1/2 study with MDNA11 in patients with advanced solid tumors
Regular and Young Investigator Award Abstracts
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Seth Baum, MD
Boca Raton Regional Hospital
Alexander Kulik, MD, MPH
Boca Raton Regional Hospital
Brian Snelling, MD
Boca Raton Regional Hospital
Ivanka Kovalyshyn, DO
Boca Raton Regional Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”